SUBSCRIBE
SUBSCRIBE
News   Drug Development

FDA Requests More Information on Halted Dynavax Technologies Corporation Study

September 19, 2008 | 
1 min read
NEW YORK - Shares of Dynavax Technologies Corp. fell Thursday as the biotechnology company responded to a Food and Drug Administration request for more information on a halted study of the developing hepatitis B vaccine Heplisav.
Preclinical
Dynavax Technologies Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Podcast
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
January 14, 2026
 · 
2 min read
 · 
Heather McKenzie
Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
January 13, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Stairs Leading to Flying Paper Plane - Success, Growth, and Freedom, 3D Render
ADCs
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
January 13, 2026
 · 
3 min read
 · 
Tristan Manalac
Medical dropper system with bag on tube 3d vector illustration. Advertising poster with laboratory equipment over copy space. Hospital emergency services promotion
Opinion
To Broaden Access to CAR Ts, Mitigate Their Side Effects
January 12, 2026
 · 
4 min read
 · 
Teresa Whalen